

## Dapagliflozin TAG summary recommendations July 2013

The enclosed policies represent DRAFT recommendations to CCGs. It is proposed that individual CCGs consider the summaries and policies enclosed within their relevant decision making groups and respond to the CCG with a decision regarding adoption/amendment of the policy – please use the attached form. Further advice on the contents of the draft policies can be sought from the contacts list at the end of the document.

### **Dapagliflozin for the management of type 2 diabetes mellitus**

Previous decision was to await for NICE guidance which has now been published.

Recommendation is as follows:

- 1) Dapagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if it is used as described for dipeptidyl peptidase-4 (DPP-4) inhibitors in Type 2 diabetes: the management of type 2 diabetes (NICE clinical guideline 87).
- 2) Dapagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes.
- 3) Dapagliflozin in a triple therapy regimen in combination with metformin and a sulfonylurea is not recommended for treating type 2 diabetes, except as part of a clinical trial.

#### **Key points discussed**

CCGs may wish to discuss with local providers where this should sit within the present treatment pathway compared to DPP-4 inhibitors.